Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 3Hodgkin Disease 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Biphenotypic, Acute 2Burkitt Lymphoma 2Teratoma 1Solid Tumors 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multi-centric Castleman's Disease 1Malignant mesenchymal tumor 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphadenopathy 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Leukemia 1Hematologic Neoplasms 1HIV Infections 1Glioma 1Glioblastoma 1

Interventions

Specimen Handling 8Magnetic Resonance Spectroscopy 7Biopsy 7pembrolizumab 6Doxorubicin 6Cyclophosphamide 6X-Rays 4Radiation 4Phantoms, Imaging 4Radiotherapy 3Nuclear Medicine Department, Hospital 3Irinotecan 3Ifosfamide 3ulixertinib 2tipifarnib 2selpercatinib 2pazopanib 2palbociclib 2liposomal doxorubicin 2ivosidenib 2fludarabine 2ensartinib 2atezolizumab 2Temozolomide 2Surveys and Questionnaires 2Gemcitabine 2Fluorodeoxyglucose F18 2Carboplatin 2Bevacizumab 2trifluridine tipiracil drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Filgrastim × 30 days × Clear all
NCT00077285 2026-05-22

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
65 enrolled
Sarcoma

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡